Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Myovant Sciences acquired for $2.9 BLN on second offer
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(4823)
•••
Post by Noteableon Oct 24, 2022 10:58am
277 Views
Post# 35043562

Myovant Sciences acquired for $2.9 BLN on second offer

Myovant Sciences acquired for $2.9 BLN on second offer October 24, 2022 - Shares of Myovant Sciences rose in premarket trading Monday after the company agreed to be acquired by Sumitovant Biopharma for $2.9 billion - three weeks after turning down a previous offer.

Myovant Sciences portfolio consists of two molecules, relugolix and MVT-602:
  • Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist that reduces sex hormones such as testosterone, estradiol, and progesterone. Relugolix is available as a 120 mg tablet and as a combination tablet (relugolix 40 mg, estradiol 1 mg and norethindrone acetate 0.5 mg). Relugolix is marketed in multiple indications internationally and is currently under investigation for certain uses.
  • MVT-602 is an oligopeptide kisspeptin-1 receptor agonist being investigated for its potential as a trigger of egg maturation in women undergoing assisted reproduction, including in vitro fertilization (IVF).
https://www.myovant.com/our-science/pipeline/#
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities